Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a global eye health company that regularly issues news on its business segments, financing activities, partnerships and product pipeline. As an ophthalmic goods manufacturer with operations in vision care, surgical products and ophthalmic pharmaceuticals, the company’s announcements cover a broad range of topics relevant to investors and those following the eye health sector.
News updates include financial results, such as quarterly revenue performance across the Vision Care, Surgical and Pharmaceuticals segments, as well as details on operating income, adjusted metrics and guidance ranges. The company also uses press releases to outline strategic plans and multi-year financial targets, describe its product pipeline in areas like dry eye, glaucoma, ocular surface pain and age-related macular degeneration, and highlight clinical-stage programs and anticipated launches across consumer, pharmaceutical, surgical and contact lens businesses.
Bausch + Lomb’s news flow also features information on capital structure and liquidity, including amendments to its credit agreement, new term loan tranches, revolving credit facilities and senior secured notes offerings, along with the intended use of proceeds for refinancing existing debt. Governance and leadership developments, such as board appointments, committee assignments and changes related to director nomination agreements, are disclosed through current reports and accompanying press releases.
In addition, the company issues news about partnerships and initiatives in eye health, including collaborations with organizations focused on glaucoma research and awareness, and sustainability programs like the ONE by ONE Recycling Program and the Every Contact Counts program. For readers tracking BLCO, this news page aggregates these updates so they can review company communications on financial performance, strategic direction, product development, governance and eye health initiatives in one place.
Bausch + Lomb (NYSE: BLCO) will release its first-quarter 2026 financial results on Wednesday, April 29, 2026, and will host a conference call and live webcast at 8 a.m. ET.
All presentation materials will be posted on the company's Investor Relations website prior to the call. Replay access will be available through May 13, 2026, with passcode 53393.
Bausch + Lomb (NYSE:BLCO) announced positive 24-month pivotal U.S. trial results for the implant-free ELIOS System for open-angle glaucoma. Key outcomes: 76% of patients achieved ≥20% unmedicated IOP reduction, mean unmedicated DIOP fell by 7.4 mmHg, and 82% were medication-free at 23 months.
The ELIOS procedure reported no intraoperative complications and a postoperative adverse event rate similar to cataract surgery. ELIOS is CE marked in Europe but has not been reviewed by the FDA in the U.S.
Bausch + Lomb (NYSE: BLCO) announced an R&D “Teach-in” webinar on March 23, 2026 at 1:30 p.m. ET covering two glaucoma programs: BL1107, a medication in development targeting vision loss plus intraocular pressure, and ELIOS™, an implant-free MIGS approach commercialized in Europe with anticipated U.S. launch in 2H 2026.
The live event will feature R&D and senior executives and will be hosted by Wells Fargo; a replay will be posted on the company Investor Relations website.
Bausch + Lomb (NYSE: BLCO) cites a new global review in Ophthalmology and Therapy showing a lifestyle-driven rise in noninfectious ocular redness from digital eye strain, dry eye, allergies and environment. The review highlights LUMIFY (brimonidine tartrate 0.025%) as a differentiated OTC option with a selective α2 mechanism, no tachyphylaxis over 29 days, and virtually no rebound redness. It also notes a preservative-free brimonidine 0.025% formulation introduced by the company in 2025 with comparable efficacy and tolerability. The paper calls for more patient education on safe OTC redness treatments.
Bausch + Lomb (NYSE: BLCO) reported Q4 2025 revenue $1.405B (up 10% reported, 7% constant currency) and FY 2025 revenue $5.101B (up 6% reported, 5% CC).
GAAP net loss was $58M Q4 and $360M FY; adjusted EBITDA was $326M Q4 and $858M FY. The company guided 2026 revenue $5.375B–$5.475B and Adj. EBITDA ex-IPR&D $1.00B–$1.05B.
Operational highlights included MIEBO Q4 sales $112M, a $1.1B dry-eye portfolio in 2025, premium IOL recovery, ongoing clinical trial recruitment, cash of $397M, and a webcast replay available through March 4, 2026.
Bausch + Lomb (NYSE: BLCO) will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8:00 a.m. ET to discuss results and provide a business update.
Materials will be posted on the Investor Relations website before the call. A replay will be available until March 4, 2026.
- Date: Wednesday, Feb. 18, 2026
- Time: 8:00 a.m. ET
- Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392
- Participant dial-in (North America): +1 (888) 506-0062
- Participant dial-in (International): +1 (973) 528-0011
- Access code: 923960
- Replay dial-in (North America): +1 (877) 481-4010; Replay passcode: 53392
Bausch + Lomb (NYSE: BLCO) announced a partnership with Glaucoma Research Foundation and The Glaucoma Foundation for Glaucoma Awareness Month in January 2026 to raise awareness and fund research into glaucoma, which affects about four million people in the U.S.
Key actions: Bausch + Lomb will launch its fifth annual fundraising challenge and match donations dollar-for-dollar up to $20,000 during January; it will also sponsor a month-long social media campaign spotlighting a glaucoma patient or advocate each day. All proceeds will support glaucoma research and education.
Bausch + Lomb (NYSE: BLCO) closed a refinancing under a Fourth Amendment to its credit agreement, establishing $2,802,125,000 of Replacement Term B loans to refinance outstanding term B loans due 2031 and 2028.
The Replacement Term Loans carry a 1.00% annual amortization with the first installment due June 30, 2026, and mature on January 15, 2031. The applicable margins are 3.75% over term SOFR or 2.75% over alternate base rate, representing a 50 bps reduction versus the prior 2031 tranche and a 25 bps reduction versus the 2028 tranche; the 2028 loans receive an effective five-plus year maturity extension to 2031.
Bausch + Lomb (NYSE: BLCO) announced that Chairman and CEO Brent Saunders, CFO Sam Eldessouky, and CMO & Head of R&D Yehia Hashad, MD will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026 at 1:30 p.m. PT (4:30 p.m. ET).
A live webcast and an audio archive will be available on the company Investor Relations website at http://ir.bausch.com/investors/events-presentations.
Bausch + Lomb (NYSE: BLCO) announced two board appointments: Eduardo C. Alfonso, MD and Steven H. Collis, effective Jan. 1, 2026. Following earlier August 2025 changes, the board will comprise 10 directors. Management says Alfonso brings deep ophthalmology expertise and Collis brings extensive CEO-level financial experience. The company framed the additions as support for accelerating strategy and pursuing significant opportunities ahead.